09.07.2018 – 18:20

BB Biotech AG

DGAP-Adhoc: BB Biotech AG admitted to the SMIM and SPI Index

DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Miscellaneous
BB Biotech AG admitted to the SMIM and SPI Index

09-Jul-2018 / 18:10 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
Media release as of July 9, 2018
 

BB Biotech AG admitted to the SMIM and SPI Index
 

After the SIX Swiss Exchange's latest regular review of index components, BB
Biotech was admitted to the SMIM Index and the SPI Index (sub-index SPI Mid).
The composition of the two indices will be adjusted after the close of trading
on September 21, 2018, effective as of September 24, 2018.

BB Biotech was previously admitted to the Stoxx Europe 600 in 2014 due to its
growing market capitalization and trading liquidity. "BB Biotech's admission to
the SMIM Index reflects our successful performance in the highly attractive
market of biotechnology," declares Dr. Daniel Koller, Head of BB Biotech's
Investment Team. "With almost 25 years of experience and an investment portfolio
of around CHF 3.5 bn, we are one of the largest investors in this field."

The SMI family, the most widely followed group of indices compiled by SIX Swiss
Exchange, comprises the 50 largest and most liquid stocks in the Swiss stock
market. The blue-chip SMI Index is the most prestigious index of stocks listed
in Switzerland and comprises the 20 largest stocks from the SPI. The SMIM, in
which BB Biotech will be a member effective September 24, 2018, comprises the
next 30 largest and most liquid stocks from the mid cap segment of the SPI. All
SMI and SMIM stocks are included in the SMI Expanded Index, which covers more
than 90% of the Swiss stock market's entire capitalization.

 

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel.
+41 44 267 67 07
Tanja Chicherio,tch@bellevue.ch

TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41
79 423 22 28
Thomas Egger,teg@te-communications.ch

www.bbbiotech.com



Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector. BB Biotech is listed in
Switzerland, Germany and Italy. Its investments are focused on listed companies
that are developing and commercializing novel medical treatments and cures. BB
Biotech's investment selection process is guided by the fundamental research and
analysis of physicians and molecular biologists. Its Board of Directors has many
years of experience in industry and science.
--------------------------------------------------------------------------------
09-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
--------------------------------------------------------------------------------

Language: English

Company:  BB BIOTECH AG

          Schwertstrasse 6

          8200 Schaffhausen

          Switzerland

Phone:    +41 52 624 08 45

E-mail:    info@bbbiotech.com

Internet: www.bbbiotech.ch

ISIN:     CH0038389992

WKN:      A0NFN3

Listed:   Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial
Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX



 

End of Announcement DGAP News Service

--------------------------------------------------------------------------------

702815  09-Jul-2018 CET/CEST